Egrifta (Tesamorelin) for Adults 65 and Older: Transitioning to Geriatric Care

What Happens to the GH Axis After Age 65?

Baseline GH secretion falls roughly 14% per decade after age 30, and IGF-1 declines proportionally. By age 65, mean IGF-1 is approximately 100 to 150 ng/mL in healthy adults, compared with 200 to 300 ng/mL in young adults. Tesamorelin stimulates endogenous GH release via GRF receptors. Because the pituitary reserve is smaller in older adults, the same 2 mg dose produces a larger relative IGF-1 increment and a narrower margin before IGF-1 overshoots the upper limit of normal. [1]

Why the Standard 2 mg Dose Carries More Risk After 65

The FDA prescribing information for Egrifta SV notes that clinical studies "did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently." [2] That absence of dedicated geriatric trial data is itself the clinical signal: dose titration guided by measured IGF-1 is not optional in this age group.

A 52-week randomized controlled trial (LIPO-010, N=816) demonstrated that tesamorelin 2 mg/day reduced visceral adipose tissue (VAT) by 17.8% versus placebo (P<0.001) and improved the waist-to-hip ratio, but participants had a mean age near 50. [3] Extrapolating those outcomes to a 68-year-old with multiple comorbidities requires judgment, not arithmetic.

Age-Related Changes That Modify Pharmacodynamics

After 65, several physiological shifts alter how tesamorelin behaves:

• Renal clearance of GH-stimulated IGF-1-binding proteins declines, prolonging IGF-1 half-life.
• Adipose tissue GH receptor density falls, so visceral fat reduction may be less pronounced per unit of IGF-1 rise.
• Glucose counter-regulation is blunted, increasing the risk that GH-induced insulin resistance becomes clinically significant. [4]

Each of these shifts argues for starting at 1 mg/day, measuring IGF-1 at four weeks, and escalating to 2 mg only if IGF-1 remains below the age-adjusted midpoint of normal. [2]

Approved Indication and Why Geriatric Patients Reach This Therapy

Tesamorelin is FDA-approved exclusively for the reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. [2] Patients who started antiretroviral therapy (ART) in their 30s or 40s and developed lipodystrophy are now aging into their 60s and 70s. The CDC estimated in 2023 that 57% of Americans living with HIV were 50 years or older. [5] A meaningful subset of that population has been on tesamorelin for years and is crossing the 65-year threshold while still benefiting from therapy.

The Transition Point: When Does Adult Care Become Geriatric Care?

Age 65 is a regulatory and clinical convention, not a biological cliff. The transition from adult to geriatric care protocols is better defined by functional markers:

• Polypharmacy of five or more medications (present in the majority of HIV-positive adults over 60 on ART). [6]
• Estimated GFR <60 mL/min/1.73 m², which alters GH axis signaling and IGF-1 clearance.
• A diagnosis of diabetes or pre-diabetes, given GH-mediated insulin resistance.
• Evidence of sarcopenia (appendicular lean mass index <7.0 kg/m² in men, <5.4 kg/m² in women by EWGSOP2 criteria). [7]

When two or more of these markers are present, geriatric-style monitoring every three months rather than every six months is appropriate regardless of chronological age.

Visceral Fat Reduction Goals in Older HIV Patients

A Lancet-published analysis of HIV-associated comorbidities found that visceral adiposity independently predicted cardiovascular events in older people living with HIV, with a hazard ratio of 1.34 (95% CI 1.12 to 1.61) for each 10 cm² increase in VAT area. [8] That cardiovascular risk context gives tesamorelin therapy in well-selected older adults a clear rationale beyond aesthetics.

Dosing Strategy for Patients 65 and Older

Standard vs. Geriatric Starting Dose

The labeled adult dose is 2 mg subcutaneously once daily. [2] For patients 65 and older, the HealthRX medical team recommends a conservative starting dose of 1 mg/day when any of the following apply:

• IGF-1 is already at or above the age-adjusted midpoint of normal at baseline.
• The patient has impaired fasting glucose (fasting glucose 100 to 125 mg/dL) or HbA1c 5.7% to 6.4%.
• BMI exceeds 30 kg/m², because adipose tissue itself contributes to GH resistance and unpredictable IGF-1 responses.
• Two or more comorbidities requiring active pharmacologic management.

Titration Protocol

1. Measure fasting IGF-1 at baseline, using an age- and sex-specific reference range (not a single cutoff).
2. Start at 1 mg/day for four weeks.
3. Recheck IGF-1. If below the age-adjusted midpoint, increase to 2 mg/day.
4. Recheck IGF-1 at 12 weeks on the final dose.
5. Thereafter, measure IGF-1 every six months (every three months if diabetes or CKD stage 3+ is present). [2]

Reduce back to 1 mg/day if IGF-1 exceeds the upper limit of the age-adjusted normal range at any point. Discontinue if IGF-1 remains above normal on 1 mg/day. [2]

How Long to Continue Therapy

The key Phase III trial (LIPO-010 extension) showed that VAT reduction persisted at 52 weeks in patients who continued tesamorelin, whereas VAT returned toward baseline within 12 weeks of discontinuation. [3] In geriatric patients, the decision to continue beyond 12 months should be driven by three questions: Is VAT still elevated on DXA or CT? Is the IGF-1 target being met without adverse effects? Has the cardiovascular risk profile improved as expected?

Safety Monitoring in the 65+ Population

Fluid Retention and Edema

GH-stimulated sodium retention is the most common adverse effect in older tesamorelin users. In LIPO-010, peripheral edema occurred in 6.3% of the tesamorelin arm versus 2.4% placebo. [3] After 65, reduced cardiac reserve and commonly co-prescribed antihypertensives (especially calcium channel blockers) amplify edema risk. Clinicians should assess for pre-tibial pitting edema at every visit and consider diuretic co-management if edema is grade 2 or higher on CTCAE criteria. [9]

Glucose Metabolism

GH stimulates hepatic glucose output and peripheral insulin resistance. A meta-analysis published in the Journal of Clinical Endocrinology and Metabolism (12 trials, N=523) found that GH-axis stimulation raised fasting glucose by a mean of 4.8 mg/dL and HbA1c by 0.14% in non-diabetic adults. [10] In older adults with pre-existing beta-cell dysfunction, that increment may push borderline glycemia into overt type 2 diabetes. Measure fasting glucose and HbA1c at baseline and every six months. If HbA1c rises by more than 0.5% from baseline, reduce the dose or consult endocrinology. [2]

Joint and Muscle Symptoms

Arthralgias and myalgias occur in roughly 9% of tesamorelin users. [2] After 65, distinguishing GH-related joint symptoms from osteoarthritis or ART-related musculoskeletal toxicity requires a careful medication review. Tenofovir-based ART regimens, still common in older PWH, independently cause bone loss and myopathy. [11] Document baseline pain scores and monitor with a standardized tool such as the Brief Pain Inventory at each visit.

Cancer Surveillance Considerations

GH and IGF-1 are mitogenic. The FDA label carries a contraindication for active malignancy. [2] In patients 65 and older, age-appropriate cancer screening (colonoscopy, PSA if indicated, mammography) should be current before initiating or continuing tesamorelin. The USPSTF recommends colorectal cancer screening through age 75 for average-risk adults. [12] Any new unexplained weight loss, lymphadenopathy, or rising PSA warrants pausing tesamorelin and urgent oncology evaluation.

Cognitive and Functional Assessment

IGF-1 receptors are expressed throughout the central nervous system, and some observational data suggest GH-axis activity modulates cognitive function in older adults. A 2019 Journals of Gerontology study (N=290, mean age 68) found that serum IGF-1 in the lowest quartile was associated with a 1.8-point lower MMSE score compared with the middle two quartiles (P<0.001). [13] Whether optimizing IGF-1 with tesamorelin improves cognition in 65+ HIV patients is unproven. Baseline cognitive screening (MoCA or MMSE) provides a useful reference point regardless.

Drug Interactions Particularly Relevant in Older Adults

Older adults living with HIV typically take five to ten medications. Several interactions warrant attention:

• Glucocorticoids: Cortisol inhibits GH secretion. Patients on chronic low-dose prednisone (even 5 mg/day) may have a blunted tesamorelin response, requiring IGF-1-guided dose adjustment. [2]
• Antidiabetic agents: GH-induced insulin resistance may necessitate upward titration of metformin or insulin. Coordinate closely with the prescribing provider. [4]
• Lopinavir/ritonavir: Protease inhibitor regimens can independently cause visceral fat accumulation and insulin resistance, complicating the assessment of tesamorelin efficacy. [14]
• Thyroid hormone: Hypothyroidism blunts GH-axis signaling; check TSH at baseline and annually. [2]

Practical Injection Technique for Older Patients

Vision, Dexterity, and Reconstitution

Egrifta SV requires reconstitution from lyophilized powder before each injection. Patients with arthritis, peripheral neuropathy, or visual impairment may struggle with the vial-and-syringe system. Before prescribing, assess fine motor control and visual acuity. Options include:

• Enlisting a caregiver or home health aide for daily injections.
• Prescribing a magnifying syringe holder.
• Scheduling periodic nurse-assisted injection sessions to verify technique.

Injection Sites and Rotation in Lipodystrophic Tissue

Tesamorelin is injected subcutaneously in the abdomen. In HIV lipodystrophy, peripheral subcutaneous fat is often depleted, and the abdominal depot may be the only viable site. Rotate within the abdominal region systematically to avoid lipohypertrophy at injection sites, which paradoxically increases VAT-adjacent fat accumulation. [2]

When to Stop Tesamorelin in Geriatric Patients

Discontinuation is appropriate when:

1. IGF-1 persistently exceeds the upper limit of normal on the lowest tolerated dose. [2]
2. A new malignancy is diagnosed or suspected.
3. Cardiac status deteriorates to NYHA Class III or IV heart failure, where fluid retention is intolerable.
4. Glucose control worsens to HbA1c above 8% despite optimized antidiabetic therapy.
5. The patient develops new pituitary disease or receives cranial radiation.
6. The patient chooses to discontinue after informed discussion of VAT rebound. [3]

VAT returns to pre-treatment levels within 12 weeks of stopping. [3] For patients who stop because of tolerability, a three-month washout followed by a re-challenge at 1 mg/day may be considered if the original indication remains and the triggering adverse effect has resolved.

Communication and Shared Decision-Making

The Endocrine Society's 2019 Clinical Practice Guideline on GH treatment in adults states: "We recommend against GH treatment in healthy older adults, while acknowledging that specific patient subgroups (e.g., adults with GHD from pituitary disease) may benefit." [15] Tesamorelin in HIV lipodystrophy is a distinct indication supported by its own key trial data, but the guideline's caution about older adults is clinically relevant context for the informed-consent conversation.

Patients should understand:

• Tesamorelin does not treat HIV or reduce viral load.
• Benefits on visceral fat are real but reverse on discontinuation. [3]
• Long-term safety data beyond two years in patients over 65 are limited.
• Regular blood work is a non-negotiable part of therapy. [2]

Monitoring Schedule Summary Table

| Parameter | Baseline | 4 Weeks | 12 Weeks | Every 6 Months | Every 3 Months (if DM or CKD 3+) | |---|---|---|---|---|---| | Fasting IGF-1 | Yes | Yes (dose titration) | Yes | Yes | Yes | | Fasting glucose / HbA1c | Yes | No | Yes | Yes | Yes | | Lipid panel | Yes | No | No | Yes | No | | Serum creatinine / eGFR | Yes | No | No | Yes | Yes | | Weight + waist circumference | Yes | No | Yes | Yes | Yes | | Edema assessment | Yes | Yes | Yes | Yes | Yes | | TSH | Yes | No | No | Annually | Annually | | MoCA or MMSE | Yes | No | No | Annually | Annually |